Filana Therapeutics, Inc. (FLNA)
| Market Cap | 61.83M -22.9% |
| Revenue (ttm) | n/a |
| Net Income | -77.90M |
| EPS | -1.61 |
| Shares Out | 48.31M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 236,044 |
| Open | 1.280 |
| Previous Close | 1.300 |
| Day's Range | 1.280 - 1.349 |
| 52-Week Range | 1.271 - 4.980 |
| Beta | -0.76 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 7, 2026 |
About FLNA
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer’s disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The... [Read more]
Financial Performance
Financial StatementsNews
Filana Therapeutics Reports Q1 2026 Financial Results and Business Update
AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tu...
Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII
AUSTIN, Texas, May 05, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tu...
Filana Therapeutics publishes simufilam preclinical data
Filana Therapeutics (FLNA) announced publication in Epilepsia of preclinical data showing that simufilam attenuated seizure progression in a well-accepted mouse model of severe TSC-related epilepsy. T...
Filana Therapeutics management to meet with Maxim
Meeting to be held on March 24-25 hosted by Maxim.
Filana Therapeutics reports Q4 EPS (26c) vs. (57c) last year
“At Filana Therapeutics (FLNA), our name reflects our deep commitment to science and to patients affected by diseases tied to filamin A dysregulation, including TSC-related epilepsy. We are driven by…
Filana Therapeutics sees 1H26 net cash use in operations $14M-$17M
The Company estimates net cash use in operations for first half of 2026 in a range from $14 to $17 million, plus a payment of a $31.25 million estimated loss…
Cassava Sciences says US DOJ has closed investigation into company
Cassava Sciences said on Thursday the U.S. Department of Justice had ended its probe into the company regarding allegations of research misconduct for its experimental Alzheimer's drug simufilam.
HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Dec. 24, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is inves...
Halper Sadeh LLC Encourages Cassava Sciences, Inc. Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Cassava Sciences, Inc. (NASDAQ: SAVA) breached their fiduciary duti...
Cassava Sciences Appoints Dawn C. Bir to the Board of Directors
AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for ce...
Filana Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference
New leadership is steering a strategic pivot to TSC-related epilepsy after Alzheimer's trial setbacks, leveraging strong preclinical results and a robust safety profile. A phase II-A proof-of-concept trial is planned for 2026, with solid financials and broad patent protection.
Cassava Reports Q2 2025 Financials Results and Provides Business Update
AUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for ce...
Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer
AUSTIN, Texas, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational tr...
Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy
AUSTIN, Texas, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel treatments for cen...
Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting
Data show that simufilam reduced seizure activity in a preclinical mouse model Presentation also highlights favorable human safety data from 1,929 patient Phase 3 program AUSTIN, Texas, June 30, 2025 ...
Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC
As SVP, Neuroscience, Dr. Bordey will lead Cassava's ongoing research and development efforts Dr. Bordey to direct the scientific evaluation of simufilam in TSC-related epilepsy, and potentially addi...
Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development
AUSTIN, Texas, April 21, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational t...
Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug
The biotechnology company Cassava Sciences failed on Wednesday to end a malicious prosecution lawsuit by doctors and short-sellers who expressed doubts about its experimental, soon-to-be-discontinued ...
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data
AUSTIN, Texas, March 25, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing a novel, investigational...
Cassava Sciences Reports 2024 Financial Results and Provides Business Update
AUSTIN, Texas, March 03, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational t...
Cassava Sciences Provides a Business Update
Topline data from Phase 3 REFOCUS-ALZ study of simufilam in patients with mild-to-moderate Alzheimer's disease expected late first-quarter/early second-quarter 2025